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Abstract
Background: The Pap test has been used for cervical cancer screening for more than four
decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is
commercially available now. These two preventive interventions should be considered
simultaneously. General population support is an important factor for the successful combination
of these interventions. The study had two objectives: 1) To assess practices, beliefs, and attitudes
regarding Pap test screening and HPV immunization; 2) To identify socio-demographic factors for
Pap screening and vaccine acceptability.
Methods: In 2006, 500 adults were invited to participate in a telephone survey in the region of
Quebec City (urban and rural population, 600 000), Canada. Some neutral and standardized
information on Pap test and HPV was provided before soliciting opinions.
Results: 471 adults (18–69 year-olds) answered the questionnaire, the mean age was 45 years, 67%
were female, and 65% had college or university degree. Eighty-six percent of women had
undergone at least one Pap-test in their life, 55% in the last year, and 15% from 1 to 3 years ago.
Among screened women, the test had been performed in the last three years in 100% of 18–30
year-olds, but only in 67% of 60–69 year-olds (P < 0.0001). Only 15% of respondents had heard of
HPV. Eighty-seven percent agreed that HPV vaccines could prevent cervical cancer, 73% that the
vaccine has to be administered before the onset of sexual activity, 89% would recommend
vaccination to their daughters and nieces. Among respondents < 25 years, 91% would agree to
receive the vaccine if it is publicly funded, but only 72% would agree to pay $100/dose.
Conclusion: There is an important heterogeneity in cervical cancer screening frequency and
coverage. Despite low awareness of HPV infection, the majority of respondents would recommend
or are ready to receive the HPV vaccine, but the cost could prevent its acceptability.
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Background
Genital Human papillomavirus (HPV) infection is the
most common sexually transmitted infection (STI). More
than 50% of sexually active women have been infected
with genital HPV at some time in their life [1-5]. Infection
prevalence of up to 82% has been reported in adolescent
and young adult women[4]. Approximately 15 virus gen-
otypes cause virtually all cases of cervical cancer [6-8].
Cervical cancer screening and treatment have been in
place for more than four decades. There is now a new
approach: vaccination against two of the most common
disease-causing HPV genotypes. The HPV vaccines, if
widely used, have the potential to prevent thousands of
cases of cervical cancer worldwide, as well as to substan-
tially reduce costs and emotional stress associated with
abnormal screening test (Pap) results[9,10]. The vaccines
target adolescent girls and young women. Several surveys
have been done with target groups as adolescents and par-
ents [11-16]. The surveys show that awareness about HPV
is very low and that many women are shocked to discover
that cervical cancer is caused by a STI.
In previously surveyed populations, estimated vaccine
acceptability was high [11-16]. However, the vaccine up-
take by adolescents and young women may be influenced
by opinions of other family members and friends.
In preparation for the implementation of HPV vaccine in
Canada, we measured acceptability, attitudes, beliefs and
practices related to cervical cancer screening and vaccina-
tion, in Canadian adults.
We hypothesize that regular cancer screening, a positive
attitude toward vaccines in general and the HPV vaccine in
particular, as well as perceived personal risk for cervical
cancer and seriousness of its consequences would be asso-
ciated with a higher HPV immunization acceptance and
vaccine up-take.
Methods
This HPV survey was conducted as a part of a study on a
number of personal health-related beliefs, attitudes and
practices, including smoking, nutrition, exercise, cardiac
disease and cervical cancer prevention.
Study population
Survey population included adult females and males aged
18–69 years. The potential participants were recruited
during February and March 2006 in 11 private outpatient
clinics in the region of Quebec City. At the moment of the
survey, 84 (of the 500 in the region) family physicians
were practicing in these clinics. Most Canadian family
physicians (78%) practice at least part of their time in pri-
vate outpatient clinics[17]. Two specially trained research
assistants recruited potential participants in the clinic's
waiting rooms. If the individual agreed to participate in
the planned telephone survey, their personal contact
information was collected and a written consent form was
signed. During the following two weeks, a polling firm
contacted participants for a telephone interview. The Sur-
vey required 13 to 15 minutes to complete.
Questionnaire
The questionnaire was built using elements of the Health
Belief Model [18]. It was pre-tested on 10 outpatients and
adjusted before the study began. Out of 56 survey items,
16 were relevant to this paper: 3 items on Pap screening,
3 on cervical cancer, 1 on HPV infection, 1 on vaccination
in general, and 8 on eventual HPV vaccination. It took 4–
6 minutes to fill out the cervical cancer screening – HPV
part of the questionnaire. Because of the hypothesis of
low awareness regarding Pap screening and HPV infec-
tion, some short, neutral and standardized information
was given to participants before asking related questions.
For Pap test it was "A Papanicolaou test (Pap test) is an
examination of the cervix; the physician takes a sample of
cells with a little stick or a brush and sends it to a labora-
tory to screen for cervical cancer". For HPV it was "The
HPV is a sexually transmitted infection and a necessary
cause of cervical cancer".
Statistical analysis
Proportions were compared by using chi-square or Fisher
exact test. Trends were evaluated with Cochran-Armitage
test. All tests of significance were two-tailed and signifi-
cance was set at 5% level. SAS Institute software (version
9.1) was used for data statistical analysis.
The Research Ethics Board Committee of Laval University
Hospital Centre approved the research protocol.
Results
Eleven out of 12 solicited clinics agreed to participate in
the study and 685 potential participants were initially
recruited (536 in 9 urban and 149 in 2 rural areas). Eight
individuals refused to respond to the questionnaire and
27 telephone numbers were invalid. As predetermined by
the study protocol, no further telephone calls were made
when 500 interviews were completed. Among those inter-
viewed, 471 (94.2%) were age eligible and their answers
were included in the analysis. The participants' average
age was 44.8 years and 67% were female. Sixty five percent
of participants had college (32%) or university (33%)
degree.
Women's opinions on cervical cancer
Fifty-seven percent of women were afraid of developing
cervical cancer sometime in their life, and 93% thought
cervical cancer has serious consequences. Cervical cancerBMC Public Health 2007, 7:304 http://www.biomedcentral.com/1471-2458/7/304
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related anxiety and perceived seriousness did not vary by
age group or level of schooling.
Cervical cancer screening
Eighty-six percent of participating women had had at least
one Pap test during their life (Table 1). Among all female
respondents, 55% had their last Pap test during the previ-
ous year, 15% from one to three years ago, and 16% three
or more years ago. The cumulative coverage with at least
one Pap test was lower in women less than 30 years (68%)
compared to older age groups (90%–93%) (P < 0.0001).
However, when an analysis of screening in the three pre-
vious years was done among those who had at least one
Pap test, a significant decrease (p < 0.0001) in screening
up-take with increasing age was observed: 100%, 86%,
74% and 67%, respectively in those under 30, 30–44, 45–
59, and 60–69 years. The two main opportunities to have
a Pap test were the annual check-up (79%) and gynaeco-
logical problems (10%).
Population HPV awareness
Only 15% of respondents had heard about HPV before
the interview. The proportion increased from 7% in those
with lower than college level of schooling, to 14% and
24% in those with college and university schooling level,
respectively (P for trend = 0.0006). No significant differ-
ences by sex (P = 0.7) or age group (P = 0.1) were observed
on this issue. However, the proportion of women who
had heard about HPV was significantly higher among
those with at least one Pap test (17%) than those with
none (4%) (P = 0.02).
Attitudes and beliefs about vaccines in general and the 
HPV vaccine in particular
Ninety percent of respondents agreed with the statement
that vaccines in general are effective against infections, but
only 47% strongly agreed. A significantly higher propor-
tion (63%) of 60–69 year-olds strongly agreed with vac-
cine usefulness compared to 34% of 18–29 year-olds (P <
0.0001) (Table 2). Results for the HPV vaccine were in the
same range: 87% agreed with the statement that the vac-
cine would reduce the risk for cervical cancer (Table 3).
No significant difference between genders was observed
regarding attitudes and beliefs about vaccines in general
(P = 1.0) or the HPV vaccine (P = 0.6). Most young
women (83%) under 30 years were ready to accept HPV
vaccination. However, the need to pay $100 per dose
diminished the acceptability of the HPV vaccine in the
youngest group (18 to 25 years). The proportion of those
who strongly agreed to accept the vaccine fell from 56% to
28% (Table 4). Seventy-three percent of respondents
agreed with the statement that the HPV vaccine should be
administered to preadolescents before the onset of sexual
activity, and 86% would recommend the vaccination to
their daughters and/or nieces. No differences between
genders were observed on these issues (P = 0.4 and 1.0,
respectively). However, the proportion of those who
would recommend the vaccine to their daughters and/or
nieces was related to the level of schooling and the time
since the last Pap test: 90%, 84%, and 83% by those with
less than college level of schooling, college and university
degree, respectively (P for trend = 0.045); 82%, 85%, and
96% by those who had a Pap test < 1 year, ; 1 to 3 years;
and > 3 years ago, respectively (P for trend = 0.03).
Nineteen percent of respondents under 30 years versus
47% among 60–69 years-old (P < 0.001) perceived HPV
vaccination as an incentive for earlier onset of sexual activ-
ity (Table 5). Ninety percent of women and 88% of men
(P = 0.5) would agree with vaccination of men if it pro-
tects women against cervical cancer.
Discussion
Despite low awareness of HPV infection, our findings sug-
gest that most young women would accept a vaccine that
protects against cervical cancer, especially if it is free of
charge and recommended by a physician. The need to pay
$100 per dose decreases by half young women's vaccine
acceptance. These results show that a potential risk for
inequitable preventive care may emerge if HPV vaccines
are by individual patient purchase. The Canadian
National Advisory Committee on Immunization[19] rec-
ommends the use of the HPV vaccine in young females
between the ages of 9 and 26. Therefore, the need to pay
for the vaccine might substantially decrease the HPV vac-
cine up-take.
Table 1: Pap test coverage
Had a test 18–29 years (N = 77) 30–44 years (N = 86) 45–59 years (N = 102) 60–69 years (N = 52) Total (N = 317)
At some time in their life 68 (65–78) 90 (81–95) 93 (86–97) 92 (81–98) 86 (81–89)
<1 year ago 58 (47–70) 62 (51–72) 53 (43–63) 40 (27–55) 55 (49–60)
1 to 3 years ago 9 (4–18) 15 (8–24) 16 (9–24) 21 (11–35) 15 (11–19)
>3 years ago 0 (0–5) 13 (7–22) 25 (17–34) 31 (12–45) 16 (13–21)
Percentages are presentedBMC Public Health 2007, 7:304 http://www.biomedcentral.com/1471-2458/7/304
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Table 2: Perceived vaccine usefulness in protection against infectious diseases
N Strongly Agree Somewhat Agree Somewhat Disagree Strongly Disagree
Age group (years)
18–29 104 34 (25–43) 53 (43–62) 13 (6–19) 1 (0–3)
30–44 118 42 (33–50) 48 (39–57) 8 (3–14) 2 (0–4)
45–59 154 48 (40–56) 41 (33–49) 10 (5–14) 1 (0–3)
60–69 91 63 (53–73) 32 (22–41) 4 (1–11) 1 (0–3)
Schooling
< College 162 56 (49–64) 35 (28–43) 7 (3–11) 1 (0–3)
College 148 36 (29–44) 51 (43–59) 11 (6–16) 1 (0–3)
University 157 45 (37–52) 45 (37–53) 9 (5–14) 1 (0–3)
Percentages and 95% CI are presented
Table 3: Perceived HPV vaccine usefulness against cervical cancer
N Strongly Agree Somewhat Agree Somewhat Disagree Strongly Disagree
Age group (years)
18–29 103 39 (29–48) 44 (34–53) 15 (8–21) 3 (0–8)
30–44 117 43 (34–52) 43 (34–52) 11 (5–17) 3 (0–7)
45–59 152 55 (47–63) 35 (27–42) 9 (5–14) 1 (0–3)
60–69 88 59 (49–69) 31 (21–40) 10 (4–17) 0 (0–4)
Schooling
< College 162 62 (55–70) 28 (21–35) 8 (4–12) 1 (0–3)
College 148 41 (33–49) 40 (32–48) 15 (9–21) 4 (1–7)
University 150 42 (34–50) 47 (39–55) 11 (6–16) 1 (0–2)
Percentages and 95% CI are presented
Table 4: HPV vaccine acceptability by young women
Taking for granted efficacy and safety of HPV vaccines: I would 
agree to receive the vaccine if
N Strongly Agree Somewhat Agree Somewhat Disagree Strongly Disagree
Free of charge
18–25 years 43 56 (41–71) 35 (21–49) 7 (0–15) 2 (0–7)
26–30 years 34 41 (25–58) 32 (17–48) 15 (3–27) 12 (1–22)
Have to pay 100$ per dose
18–25 years 39 28 (14–42) 44 (28–59) 23 (10–36) 5 (0–12)
26–30 years 25 28 (10–46) 56 (37–75) 16 (2–30) 0 (0–13)
If recommended by physician
18–25 years 43 79 (67–91) 16 (5–27) 5 (0–11) 0 (0–14)
26–30 years 34 50 (33–67) 32 (17–48) 12 (1–23) 6 (0–14)
Percentages and 95% CI are presentedBMC Public Health 2007, 7:304 http://www.biomedcentral.com/1471-2458/7/304
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The proportion of respondents who have heard about
HPV (15%) has not changed from what was reported in
Ontario adolescents (13%)[20]. These findings are also in
the same range with those reported in other countries [21-
23]. However, in our study, a higher level of schooling
was associated with more awareness about HPV.
Overall, opinions on vaccine usefulness in the prevention
of infectious diseases are positive. However, as in a recent
USA survey [21-23], a disturbing trend of less positive atti-
tudes toward vaccination in younger and more educated
populations was noted.
Certain results present a challenge concerning the HPV
vaccine use and its potential consequences. Willingness to
recommend the vaccine to daughters/nieces was similar to
that obtained in UK parents (80%)[23], and was higher
when compared to US parents' willingness (55%–67%)
[24]. However, in our study, only 72% of respondents
agreed that the vaccine should be administered to pread-
olescents, and 31% expressed concerns about possible
earlier onset of sexual activity if the vaccines were admin-
istered early in life. These results suggest that HPV vaccine
up-take by preadolescents should not be taken for
granted. Contrary to our initial hypothesis, a higher pro-
portion of females who had less regular screening tests
were willing to recommend an HPV vaccine to their
daughters/nieces. Future educational messages and aware-
ness of HPV will play a key role in vaccine acceptance.
Limitations of this study include the non-random sample
of participants recruited in outpatient clinics, the absence
of knowledge on non participant characteristics and the
limited recruitment area. Since HPV vaccines will be
administered in a primary care setting, we concur with the
other investigators[25], that it is useful to use clinic-based
samples. Due to the exploratory nature of the present
study, we did not ask questions about previous Pap test
results, parenthood or sexual behaviour. Although we
used Health Belief Model approaches in the questionnaire
construction, we did not collect sufficient information for
eventual behaviour predictions. More elaborate studies
are needed for this purpose.
The large sample size, high rate of participation, recruit-
ment in both urban and rural areas, and results obtained
both in women and men make this survey results useful
for planning public health interventions regarding cervi-
cal cancer screening and eventual HPV vaccine implemen-
tation.
Larger periodic nationwide studies on acceptability,
knowledge and attitudes about prevention issues will be
needed.
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